These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 33895475)
21. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frederiksen LSF; Zhang Y; Foged C; Thakur A Front Immunol; 2020; 11():1817. PubMed ID: 32793245 [TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2: Unique Challenges of the Virus and Vaccines. Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900 [TBL] [Abstract][Full Text] [Related]
23. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review. Chauhan N; Soni S; Gupta A; Aslam M; Jain U J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225 [TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Mistry P; Barmania F; Mellet J; Peta K; Strydom A; Viljoen IM; James W; Gordon S; Pepper MS Front Immunol; 2021; 12():809244. PubMed ID: 35046961 [TBL] [Abstract][Full Text] [Related]
25. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Sharma O; Sultan AA; Ding H; Triggle CR Front Immunol; 2020; 11():585354. PubMed ID: 33163000 [TBL] [Abstract][Full Text] [Related]
26. A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. Karnik M; Beeraka NM; Uthaiah CA; Nataraj SM; Bettadapura ADS; Aliev G; Madhunapantula SV Mol Neurobiol; 2021 Sep; 58(9):4535-4563. PubMed ID: 34089508 [TBL] [Abstract][Full Text] [Related]
27. COVID-19 vaccines: what do we know so far? Dhillon P; Altmann D; Male V FEBS J; 2021 Sep; 288(17):4996-5009. PubMed ID: 34288409 [TBL] [Abstract][Full Text] [Related]
28. COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts. Rashedi R; Samieefar N; Masoumi N; Mohseni S; Rezaei N J Med Virol; 2022 Apr; 94(4):1294-1299. PubMed ID: 34796525 [TBL] [Abstract][Full Text] [Related]
29. The 2020 race towards SARS-CoV-2 specific vaccines. Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775 [TBL] [Abstract][Full Text] [Related]
32. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. Rosati M; Agarwal M; Hu X; Devasundaram S; Stellas D; Chowdhury B; Bear J; Burns R; Donohue D; Pessaint L; Andersen H; Lewis MG; Terpos E; Dimopoulos MA; Wlodawer A; Mullins JI; Venzon DJ; Pavlakis GN; Felber BK PLoS Pathog; 2021 Sep; 17(9):e1009701. PubMed ID: 34551020 [TBL] [Abstract][Full Text] [Related]
33. COVID-19 vaccines: concerns beyond protective efficacy and safety. Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347 [TBL] [Abstract][Full Text] [Related]
34. Promise and challenges in the development of COVID-19 vaccines. Chen W Hum Vaccin Immunother; 2020 Nov; 16(11):2604-2608. PubMed ID: 32703069 [TBL] [Abstract][Full Text] [Related]
35. DNA vaccines against COVID-19: Perspectives and challenges. Silveira MM; Moreira GMSG; Mendonça M Life Sci; 2021 Feb; 267():118919. PubMed ID: 33352173 [TBL] [Abstract][Full Text] [Related]
36. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631 [TBL] [Abstract][Full Text] [Related]
38. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants. Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM Elife; 2022 Aug; 11():. PubMed ID: 36004719 [TBL] [Abstract][Full Text] [Related]
39. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087 [TBL] [Abstract][Full Text] [Related]
40. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Hodgson SH; Mansatta K; Mallett G; Harris V; Emary KRW; Pollard AJ Lancet Infect Dis; 2021 Feb; 21(2):e26-e35. PubMed ID: 33125914 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]